Adagrasib is a novel targeted therapy for the KRAS G12C mutation and has not yet been officially approved for sale in mainland China. Patients needing this drug must obtain it through specific legal channels and pay attention to several key considerations.

Is it available in China?

1. As of April 2026, Adagrasib (brand name KRAZATI) has not been approved for marketing in mainland China.

2. The drug received accelerated approval from the U.S. FDA in 2022 for the treatment of KRAS G12C-mutated non-small cell lung cancer (as monotherapy) and colorectal cancer (in combination with cetuximab), but it has not yet completed registration in China.

3. Domestic patients cannot purchase it through general hospital pharmacies.

What are the purchasing channels?

1. Hong Kong and Macau:

(1) Adagrasib is already available in Hong Kong and Macau. Patients can visit a正规 hospital in Hong Kong or Macau, obtain a prescription from a local doctor, and purchase the drug at a pharmacy in those regions.

(2) This option is suitable for patients who can travel to Hong Kong or Macau for a short period.

2. Overseas medication purchase:

(1) Through reliable overseas pharmacies or medical service agencies.

(2) Need to ensure the authenticity of the drug source and transport conditions (this drug requires room temperature storage, and the desiccant in the bottle must not be removed).

(3) It is recommended to choose large international pharmacies with cold chain guarantees.

4. Clinical trials:

(1) Check major domestic cancer hospitals or drug clinical trial registration platforms for any ongoing clinical trials involving Adagrasib (e.g., the China extension cohorts of the KRYSTAL series studies).

(2) If enrolled, the drug can be obtained free of charge, subject to strict inclusion and exclusion criteria.

5. Cross-border telemedicine:

(1) Some international medical institutions provide services that include remote consultation followed by mailing the medication.

(2) Need to confirm customs policies and whether the drug is permitted for import; personal use quantities generally should not exceed one course of treatment.

Precautions when purchasing

1. Must have a KRAS G12C mutation test report:

(1) Adagrasib is only indicated for patients with KRAS G12C mutation positivity; both non-small cell lung cancer and colorectal cancer require this driver gene mutation.

(2) Prior to purchase, a validated genetic test (tumor tissue or plasma sample) must be completed, and a report is required to obtain a prescription.

2. Choose legitimate channels and beware of counterfeit drugs:

(1) Do not obtain the drug through informal online platforms or personal resale.

(2) Targeted therapies are expensive, and the risk of counterfeit drugs is high.

3. Consult a doctor; do not self-medicate:

(1) For non-small cell lung cancer, the drug is used as monotherapy (600 mg twice daily); for colorectal cancer, it must be combined with intravenous cetuximab.

(2) In the combination regimen, Adagrasib should not be used alone for colorectal cancer.

(3) Must be guided by an oncologist familiar with this drug; do not decide on dosage or administration on your own.